Epic Unveils AI Overhaul at Annual Customer Meeting
At the recent annual customer meeting in Wisconsin, Epic CEO Judy Faulkner made a significant announcement regarding the integration of new artificial intelligence features into the company’s electronic health records system. Among these new features is an AI scribe powered by Microsoft, designed to compete with similar products from health tech unicorns like Abridge. Additionally, Epic will be introducing AI assistants targeted at doctors, patients, and administrative staff.
With Epic holding over 40% of the EHR market for hospitals, the company’s approach to AI reflects its dominance in the industry. While other companies have been quick to announce new AI tools and technologies, Epic has been more deliberate in its approach. STAT’s Brittany Trang delves into the details of Epic’s AI overhaul and why the company’s methodical approach sets it apart from the competition.
Study Challenges Beliefs About Brain Reorganization Post-Amputation
Neuroscientists have long believed that the brain undergoes reorganization when a body part is amputated. However, a new study has challenged this assumption. Researchers conducted a study on three individuals before and after they had a hand amputated, and the results were surprising. Brain images taken before and six months after amputation showed striking similarities, suggesting that the brain’s map of the body remains largely unchanged following limb loss.
The implications of this study could be significant, potentially changing the way therapy is delivered and prostheses are prescribed. Biomedical engineer Jacob George shared his insights on the study’s findings with STAT’s Veronica Paulus. Experts are now grappling with the implications of this research and the questions it raises about our understanding of the brain’s response to amputation.
Sarepta’s Gene Therapy Saga Leaves Patients of Other Disorders Behind
The ongoing saga of Sarepta’s gene therapy for Duchenne muscular dystrophy has garnered significant attention in the biotech world. However, amidst the spotlight on Duchenne, another community has been left reeling. Sarepta recently withdrew from a longstanding commitment to develop gene therapies for limb-girdle muscular dystrophy, a group of over 30 rare and debilitating muscle disorders.
For families affected by these disorders, Sarepta’s decision was devastating. After years of waiting for progress on therapies, the focus on Duchenne has left them feeling abandoned. STAT’s Jason Mast explores the impact of Sarepta’s shift in priorities and how families are coping with yet another disappointment in their pursuit of treatments for these rare conditions.
CDC Advisory Panel Member Expresses Distrust in CDC
Robert Malone, a new member of the CDC’s Advisory Committee on Immunization Practices, recently expressed his lack of trust in the CDC. In a blog post, Malone stated that he no longer believes that the information presented to the ACIP by the CDC is transparent, accurate, and unbiased. This sentiment was shared in response to an analysis of data on Merck’s RSV monoclonal antibody for babies, which Malone and other panel members voted to recommend.
The analysis, published by the Brownstone Institute, raised questions about the transparency and accuracy of CDC data. Malone, known for questioning the safety of Covid-19 vaccines, has cast doubt on the CDC’s handling of immunization recommendations. The controversy surrounding monoclonal antibody shots for RSV underscores the ongoing debate over vaccine safety and efficacy.
Reevaluating the Use of Statin Drugs
Determining whether statin drugs are the right choice for an individual involves weighing the potential benefits and risks. A new model for estimating the risk of atherosclerotic cardiovascular disease has raised questions about who should be prescribed statins. While the model drew praise for its inclusivity, it also raised concerns about the number of individuals who may no longer qualify for statin therapy.
Establishing thresholds for determining who should receive statins remains a challenge for medical organizations. A recent research letter published in JAMA Cardiology sheds light on what different thresholds would look like and how they could impact treatment decisions. STAT’s Liz Cooney explores the complexities of determining the appropriate use of statin drugs based on individual risk profiles.
In conclusion, the latest developments in AI integration, brain reorganization post-amputation, gene therapy priorities, CDC transparency, and statin drug usage highlight the evolving landscape of healthcare and medicine. As researchers, clinicians, and policymakers continue to navigate these complex issues, the ultimate goal remains providing the best possible care for patients and improving health outcomes for all.
